What Gilead Sciences stock is offering investors right now

Gilead Sciences (GILD) is back on investors’ radar as its shares trade around $148.95, with recent returns over the past month and past 3 months prompting closer attention to its valuation and fundamentals.

At a share price of $148.95, Gilead Sciences has a 90 day share price return of 20.21% and a 1 year total shareholder return of 32.01%. The 3 year and 5 year total shareholder returns of 104.08% and 178.72% respectively indicate that momentum has been building over a longer stretch.

If Gilead’s run has you thinking about where else growth stories might emerge, it could be a good moment to look at 28 healthcare AI stocks as another healthcare themed opportunity set.

With Gilead trading at $148.95, sitting around 5% below the average analyst price target and flagged with a strong value score, you have to ask: is there still mispricing here, or is the market already baking in future growth?

Most Popular Narrative: 12.4% Overvalued

Compared with the last close of $148.95, the most followed narrative points to a fair value of $132.57, putting the current price above that mark and hinging heavily on how HIV and oncology evolve from here.

The launch and scaling of innovative products (Yeztugo, Trodelvy first line, Livdelzi) position Gilead to deliver a more favorable product mix and premium pricing, driving higher gross margins and improving long term earnings trajectory as portfolio diversification reduces overexposure to legacy products.

Want to see what kind of revenue path and margin profile this narrative is baking in, and how that translates into a richer future earnings multiple and discount rate assumptions that justify a higher price tag than many investors might expect at first glance.

Result: Fair Value of $132.57 (OVERVALUED)

However, this hinges on successful HIV and oncology execution, with policy or pricing setbacks and tougher competition serving as potential triggers for a rethink of that upbeat narrative.

Another View: Earnings Multiple Points To A Different Story

While the narrative model suggests Gilead Sciences is 12.4% overvalued at $148.95 versus a fair value of $132.57, the P/E picture looks quite different. Gilead trades on 21.7x earnings, compared with peers at 43.7x and a fair ratio of 28.5x. That gap suggests the risk may be less about overpaying today and more about whether the market ever re-rates the stock toward that fair ratio.

Next Steps

If this mix of upside and risk has you on the fence, it is worth checking the data now and weighing it against your own expectations, and you can round that out by looking at 5 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Gilead has sharpened your focus, do not stop here. Use the Simply Wall St Screener to keep finding opportunities that match how you like to invest.

• Target potential mispricing by scanning for companies that look attractively valued on both earnings and balance sheet quality through our 49 high quality undervalued stocks.
• Strengthen your income focus by reviewing our hand picked list of 13 dividend fortresses that aim to pair yield with resilience.
• Reduce portfolio stress by checking out a curated set of 76 resilient stocks with low risk scores that score well on financial robustness and risk factors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.